In a research report released Tuesday, Brean Capital analyst Jason Wittes assumed coverage on shares of Inovio Pharmaceuticals Inc (NASDAQ:INO), with a Buy rating …
Inovio Pharmaceuticals Inc (NASDAQ:INO) shares popped 25.12% to $8.
Inovio Pharmaceuticals Inc (NASDAQ:INO) announced it will advance its DNA vaccine for MERS (Middle East Respiratory Syndrome) into a phase I clinical trial in …
Inovio Pharmaceuticals Inc (NASDAQ:INO), closed its previously announced underwritten public offering of 10,925,000 shares of the Company’s common stock, including 1,425,000 shares of …
Inovio Pharmaceuticals Inc (NASDAQ:INO) announced preliminary data showing that its INO-3112 DNA-based immunotherapy generated strong CD8+ T cell responses in 3 of 4 patients …
Inovio Pharmaceuticals Inc (NASDAQ:INO) announced that the company has been selected to receive a grant from the Defense Advanced Research Projects Agency (DARPA) …
Inovio Pharmaceuticals, Inc. (Nasdaq:INO) announced today that Chief Operating Officer, Dr.
Inovio Pharmaceuticals Inc (Nasdaq:INO) announced the appointment of Scott M. White, M.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced that the company and its academic collaborators, including the University of Pennsylvania(UPenn), were awarded a new five-year $16 …
In a research report published today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Inovio Pharmaceuticals (NASDAQ:INO) with a $20 price …
